MEDXF News and Press, Medexus Pharmaceuticals Inc From 03/06/23

TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023. Event : 35th Annual Roth Confer...

Medexus Pharmaceuticals Inc Q3 2023 Results Conference Call February 09, 2023 08:00 AM ET Company Participants Victoria Rutherford - Investor Relations Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Officer Conference Call Partic...

Results reflect growth across all leading prescription products, demonstrating continued track record of strong overall performance Management to host conference call at 8:00 AM Eastern Time on Thursday, February 9, 2023 TORONTO and CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Medexus...

Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -...

TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrro...

TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quart...

Medexus Pharmaceuticals ( OTCQX:MEDXF ) said it expects it will take its German partner medac up to a year or more to collect and submit the information requested by the U.S. Food and Drug Administration (FDA) for their therapy treosulfan. Medac had resubmitted a new drug app...

Medexus Pharmaceuticals ( OTCQX:MEDXF ) ( TSX: MDP:CA ) said its FQ3 revenue is expected to be between $28.5M and $29.0M, an increase of 34% Y/Y and at least 3% Q/Q. The company said the primary drivers for the revenue increase were increases in net sales across the company's port...

TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal ...

Medexus Pharmaceuticals Inc. (MEDXF) Q2 2023 Earnings Conference Call November 9, 2022 08:00 ET Company Participants Victoria Rutherford - Investor Relations, Adelaide Capital Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Office...